Summary:
- WeightWatchers (WW, Financial) is facing financial struggles amid new GLP-1 drug compounding restrictions.
- Wall Street analysts see significant potential upside in the stock despite current challenges.
- GuruFocus estimates suggest a substantial increase in fair value over the next year.
Amid increasing restrictions on GLP-1 drug compounding, WeightWatchers (WW) is struggling to stay afloat, raising concerns about potential bankruptcy. Once a dominant player in the weight loss industry, the company is now fighting to sustain its market position as new regulations challenge its core offerings. Currently, WeightWatchers stock has nosedived to approximately 15 cents, illustrating its precarious position.
Wall Street Analysts Forecast
According to forecasts by three analysts, the average one-year price target for WW International Inc (WW, Financial) stands at $1.00, with projections ranging from a high of $1.10 to a low of $0.90. This average target suggests a substantial potential upside of 152.78% from the current price of $0.40. Investors seeking more detailed information can find it on the WW International Inc (WW) Forecast page.
The consensus recommendation from three brokerage firms places WW International Inc (WW, Financial) at an average brokerage recommendation of 3.0, indicating a "Hold" status. The rating system spans from 1, representing a Strong Buy, to 5, indicating a Sell recommendation.
From the perspective of GF Value, GuruFocus estimates project WW International Inc (WW, Financial) to reach a value of $2.61 in one year, implying a potential upside of 559.76% from the current price of $0.3956. The GF Value, a proprietary GuruFocus metric, represents the estimated fair value at which the stock should trade, derived from historical trading multiples, historical business growth, and projected future performance. Additional data is available on the WW International Inc (WW) Summary page.
